


## HDL-16

Cat. No.:	HY-161343
CAS No.:	2373280-36-3
Molecular Formula:	C <sub>14</sub> H <sub>11</sub> BrN <sub>2</sub> O
Molecular Weight:	303.15
Target:	P2Y Receptor; Necroptosis
Pathway:	GPCR/G Protein; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HDL-16 is a potent P2Y <sub>14</sub> R antagonist with an IC <sub>50</sub> of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	P2Y <sub>14</sub> Receptor 0.3095 nM (IC <sub>50</sub> )									
<b>In Vitro</b>	<p>The N atom on benzoxazole ring of HDL-16 forms a hydrogen bond with Tyr102 residue, and the amine group also forms a hydrogen bond interaction with His184 residue in the binding pocket of P2Y<sub>14</sub>R<sup>[1]</sup>.</p> <p>HDL-16 has almost no cytotoxicity under the concentration of 10 μM in HT-29 cells<sup>[1]</sup>.</p> <p>HDL-16 can inhibit the necroptosis of HT-29 cells (with 20 ng/mL TNFα plus 20 μM zVAD-fmk (HY-16658B) and Smac mimetic (BV6, 2 μM) for 8 h)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>HDL-16 (10 μM or 20 μM; 100 μL; Rectally administered; daily; 6 days) with high-dose significantly suppresses colitis symptoms and leads to maintained gut barrier integrity in the mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male, 7-8-week-old, P2Y<sub>14</sub>R<sup>fl/fl</sup> Vil-cre (P2Y<sub>14</sub>R<sup>ΔIEC</sup>), P2Y<sub>14</sub>R<sup>fl/fl</sup> Lyz2-cre and WT mice with C57BL/6 J background<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 μM or 20 μM; 100 μL</td> </tr> <tr> <td>Administration:</td> <td>Rectally administered; daily; 6 days</td> </tr> <tr> <td>Result:</td> <td>           With high-dose showed dramatically less body weight loss and lower Disease Activity Index (DAI) than Dextran sodium sulfate (DSS; 36-50 kDa; 3% w/v; drinking water for 7 days)-exposed mice.            With high-dose improved DSS-induced inflammatory infiltration and tissue damage.            With high-dose resulted in a prominently suppression in necroptosis of the IECs in DSS-treated mice.         </td> </tr> </table>		Animal Model:	Male, 7-8-week-old, P2Y <sub>14</sub> R <sup>fl/fl</sup> Vil-cre (P2Y <sub>14</sub> R <sup>ΔIEC</sup> ), P2Y <sub>14</sub> R <sup>fl/fl</sup> Lyz2-cre and WT mice with C57BL/6 J background <sup>[1]</sup>	Dosage:	10 μM or 20 μM; 100 μL	Administration:	Rectally administered; daily; 6 days	Result:	With high-dose showed dramatically less body weight loss and lower Disease Activity Index (DAI) than Dextran sodium sulfate (DSS; 36-50 kDa; 3% w/v; drinking water for 7 days)-exposed mice. With high-dose improved DSS-induced inflammatory infiltration and tissue damage. With high-dose resulted in a prominently suppression in necroptosis of the IECs in DSS-treated mice.
Animal Model:	Male, 7-8-week-old, P2Y <sub>14</sub> R <sup>fl/fl</sup> Vil-cre (P2Y <sub>14</sub> R <sup>ΔIEC</sup> ), P2Y <sub>14</sub> R <sup>fl/fl</sup> Lyz2-cre and WT mice with C57BL/6 J background <sup>[1]</sup>									
Dosage:	10 μM or 20 μM; 100 μL									
Administration:	Rectally administered; daily; 6 days									
Result:	With high-dose showed dramatically less body weight loss and lower Disease Activity Index (DAI) than Dextran sodium sulfate (DSS; 36-50 kDa; 3% w/v; drinking water for 7 days)-exposed mice. With high-dose improved DSS-induced inflammatory infiltration and tissue damage. With high-dose resulted in a prominently suppression in necroptosis of the IECs in DSS-treated mice.									

### REFERENCES

---

[1]. Chunxiao Liu, et al. Targeting P2Y<sub>14</sub>R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. Nat Commun. 2024 Mar 7;15(1):2083.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA